The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.
X4 Pharmaceuticals (XFOR) announced on Wednesday that it will reduce its workforce by 50% as part of a strategic restructuring.
Add Asianet Newsable as a Preferred Source
The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said. The strategic restructuring is aimed at aligning resources to complete the late-stage trial in patients with moderate and severe chronic neutropenia, it added.
Shares of the company rose 2% in the pre-market session at the time of writing.
Get updates to this developing story <directly on Stocktwits.<